The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells

Lyndsay V. Rhodes, Ashley M. Nitschke, H. Chris Segar, Elizabeth C. Martin, Jennifer L. Driver, Steven Elliott, Seung Yoon Nam, Meng Li, Kenneth Nephew, Matthew E. Burow, Bridgette M. Collins-Burow

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic targeting in a number of ontological entities, particularly in the setting of aggressive therapy-resistant disease. Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line. Additionally, recent work has demonstrated that these agents can alter the expression profile of microRNA signatures in malignant cells. Using an unbiased microRNA microarray analysis, changes in miRNA expression of MCF-7TN-R cells treated with TSA for 24 h were analyzed. We observed significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs in response to TSA treatment. Our results demonstrate that the HDACi, TSA, exerts anticancer activity in the apoptosis-resistant MCF-7TN-R breast carcinoma cell line. This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype.

Original languageEnglish
Pages (from-to)10-16
Number of pages7
JournalOncology Reports
Volume27
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

trichostatin A
Histone Deacetylase Inhibitors
MicroRNAs
Apoptosis
Breast Neoplasms
Cell Line
Microarray Analysis
Drug Resistance
Epigenomics
Up-Regulation
Therapeutics
Down-Regulation
Phenotype

Keywords

  • Breast cancer
  • Drug resistance
  • Histone deacetylase
  • MCF-7
  • microRNA
  • Trichostatin A

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rhodes, L. V., Nitschke, A. M., Segar, H. C., Martin, E. C., Driver, J. L., Elliott, S., ... Collins-Burow, B. M. (2012). The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncology Reports, 27(1), 10-16. https://doi.org/10.3892/or.2011.1488

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. / Rhodes, Lyndsay V.; Nitschke, Ashley M.; Segar, H. Chris; Martin, Elizabeth C.; Driver, Jennifer L.; Elliott, Steven; Nam, Seung Yoon; Li, Meng; Nephew, Kenneth; Burow, Matthew E.; Collins-Burow, Bridgette M.

In: Oncology Reports, Vol. 27, No. 1, 01.2012, p. 10-16.

Research output: Contribution to journalArticle

Rhodes, LV, Nitschke, AM, Segar, HC, Martin, EC, Driver, JL, Elliott, S, Nam, SY, Li, M, Nephew, K, Burow, ME & Collins-Burow, BM 2012, 'The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells', Oncology Reports, vol. 27, no. 1, pp. 10-16. https://doi.org/10.3892/or.2011.1488
Rhodes, Lyndsay V. ; Nitschke, Ashley M. ; Segar, H. Chris ; Martin, Elizabeth C. ; Driver, Jennifer L. ; Elliott, Steven ; Nam, Seung Yoon ; Li, Meng ; Nephew, Kenneth ; Burow, Matthew E. ; Collins-Burow, Bridgette M. / The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. In: Oncology Reports. 2012 ; Vol. 27, No. 1. pp. 10-16.
@article{6c944ab8b9da421cbd1b3b05815b4c51,
title = "The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells",
abstract = "The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic targeting in a number of ontological entities, particularly in the setting of aggressive therapy-resistant disease. Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line. Additionally, recent work has demonstrated that these agents can alter the expression profile of microRNA signatures in malignant cells. Using an unbiased microRNA microarray analysis, changes in miRNA expression of MCF-7TN-R cells treated with TSA for 24 h were analyzed. We observed significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs in response to TSA treatment. Our results demonstrate that the HDACi, TSA, exerts anticancer activity in the apoptosis-resistant MCF-7TN-R breast carcinoma cell line. This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype.",
keywords = "Breast cancer, Drug resistance, Histone deacetylase, MCF-7, microRNA, Trichostatin A",
author = "Rhodes, {Lyndsay V.} and Nitschke, {Ashley M.} and Segar, {H. Chris} and Martin, {Elizabeth C.} and Driver, {Jennifer L.} and Steven Elliott and Nam, {Seung Yoon} and Meng Li and Kenneth Nephew and Burow, {Matthew E.} and Collins-Burow, {Bridgette M.}",
year = "2012",
month = "1",
doi = "10.3892/or.2011.1488",
language = "English",
volume = "27",
pages = "10--16",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells

AU - Rhodes, Lyndsay V.

AU - Nitschke, Ashley M.

AU - Segar, H. Chris

AU - Martin, Elizabeth C.

AU - Driver, Jennifer L.

AU - Elliott, Steven

AU - Nam, Seung Yoon

AU - Li, Meng

AU - Nephew, Kenneth

AU - Burow, Matthew E.

AU - Collins-Burow, Bridgette M.

PY - 2012/1

Y1 - 2012/1

N2 - The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic targeting in a number of ontological entities, particularly in the setting of aggressive therapy-resistant disease. Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line. Additionally, recent work has demonstrated that these agents can alter the expression profile of microRNA signatures in malignant cells. Using an unbiased microRNA microarray analysis, changes in miRNA expression of MCF-7TN-R cells treated with TSA for 24 h were analyzed. We observed significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs in response to TSA treatment. Our results demonstrate that the HDACi, TSA, exerts anticancer activity in the apoptosis-resistant MCF-7TN-R breast carcinoma cell line. This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype.

AB - The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic targeting in a number of ontological entities, particularly in the setting of aggressive therapy-resistant disease. Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line. Additionally, recent work has demonstrated that these agents can alter the expression profile of microRNA signatures in malignant cells. Using an unbiased microRNA microarray analysis, changes in miRNA expression of MCF-7TN-R cells treated with TSA for 24 h were analyzed. We observed significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs in response to TSA treatment. Our results demonstrate that the HDACi, TSA, exerts anticancer activity in the apoptosis-resistant MCF-7TN-R breast carcinoma cell line. This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype.

KW - Breast cancer

KW - Drug resistance

KW - Histone deacetylase

KW - MCF-7

KW - microRNA

KW - Trichostatin A

UR - http://www.scopus.com/inward/record.url?scp=84855283939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855283939&partnerID=8YFLogxK

U2 - 10.3892/or.2011.1488

DO - 10.3892/or.2011.1488

M3 - Article

C2 - 21971930

AN - SCOPUS:84855283939

VL - 27

SP - 10

EP - 16

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -